Semaglutide is a GLP-1 medication made by Novo Nordisk
Intriguingly, a first-of-its-kind SGLT2i trial and secondary analysis in patients with HFmrEF and HFpEF showed a 29% reduction in patients' risk of HHF [74, 75], although this effect was diminished in patients with EF 65%
Why Sugar Is Different (and Sneakier) Sugar occupies a strange place in human physiology
Additionally, factors like diet, exercise, and overall adherence to the treatment plan can influence outcomes
The diagnosis at an advanced stage, when a cure is rare, together with resistance to conventional therapy, have a dramatic impact in patient survival 4
Placidi, M., Di Emidio, G., Virmani, A., D'Alfonso, A., Artini, P